Questions about the real clinical potential of PE 22-28 for neuroplasticity
Posted by optimizer_jenna in Research & News - 54 points, 3 comments.
I have been reading more about the TREK-1 channel blockade research lately, specifically regarding the peptide PE 22-28. It is actually quite fascinating how it differs from traditional SSRIs since the animal models suggest it might work much faster for antidepressant effects by promoting synaptogenesis. I found a recent discussion on the mechanism of spadin-derived peptides and it makes me wonder about the actual translation to humans.
Tbh, I am a bit skeptical because most of this is still in the preclinical stage. It is easy to get excited about rapid neurogenesis, but the human safety profile for blocking these potassium channels is still so unknown. I am curious if anyone here has seen any recent papers that move beyond rodent studies.
For me, the idea of fast-acting neuroplasticity tools is very appealing for longevity and brain health, but I want to see more concrete data before I get too optimistic. Is the TREK-1 pathway actually a reliable target for human mood regulation, or is it perhaps too specific to be a practical therapeutic? I would love to see some actual human trials soon.
Comments
- steph219: I agree with your skepticism about the transition from rodents to people, it is a huge jump, especially with something as sensitive as potassium channels. I have been tracking the spadin research too, and while the mechanism of action looks cool on paper, the risk of off-target effects in the central nervous system seems high. I have not seen any human trials yet, but i have been reading about how TREK-1 expression varies wildly between individuals, which might make a one-size-fits-all approach
- optimizer_jenna: That point about TREK-1 expression variation is actually quite scary. If expression levels are that inconsistent between people, a standard dose could be totally different for everyone. Tbh, I am also mainly looking at synaptic density for long-term health, but the off-target risks you mentioned make me very nervous. Do you think that variability might make the side effects even more unpredictable?
- gina_zone2: Tbh I am right there with you on the TREK-1 variation. If expression is that inconsistent, the results for me would probably be totally different from someone else. It makes the whole thing feel like a gamble without more data on individual baseline levels. Does anyone know if there are any papers looking at that expression variance?
- optimizer_jenna: That is EXACTLY why I am so hesitant. If the baseline expression varies that much between people, a standard dose could be useless or too much. It makes the research feel a bit incomplete, tbh. I have not found any papers on expression variance yet, but if you find one, please share it. I really want to see if there is a way to predict who would actually benefit.
Community discussion - research and educational context only. Not medical advice.